- Home
- INTR vs TERN Comparison
INTR vs TERN Comparison
Compare INTR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | TERN |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | INTR | TERN |
|---|---|---|
| Price | $8.73 | $37.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.00 | ★ $48.60 |
| AVG Volume (30 Days) | ★ 3.9M | 1.9M |
| Earning Date | 02-11-2026 | 03-19-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 51.09 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,056,044,206.00 | N/A |
| Revenue This Year | $84.84 | N/A |
| Revenue Next Year | $25.22 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | ★ 34.63 | N/A |
| 52 Week Low | $4.86 | $1.87 |
| 52 Week High | $10.36 | $48.26 |
Technical Indicators
Market Signals| Indicator | INTR | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 54.20 |
| Support Level | $8.87 | $37.02 |
| Resistance Level | $10.11 | $39.60 |
| Average True Range (ATR) | 0.48 | 2.16 |
| MACD | -0.08 | 0.22 |
| Stochastic Oscillator | 14.66 | 70.18 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.